Review Article
Antiepidermal Growth Factor Receptor Monoclonal Antibodies: Applications in Colorectal Cancer
Table 7
Trials using anti-EGFR MAbs with other targeted therapies in chemotherapy-resistant mCRC in KRAS WT patients.
| Trial (author) | Phase |
Protocol |
Number enrolled | Results
|
HR (95% CI) | value | PFS | OS |
| AGITG CO.20 (Siu et al.) [31] | III | Cetuximab + brivanib alaninate cetuximab | 376 374 | 5.0 mos. 3.4 mos. | 8.8 mos. 8.1 mos. | PFS: 0.72 (0.62–0.84) OS: 0.88 (0.74–1.03) | <0.0001 0.12 |
| — (Watkins et al.) [32] |
II/III | Dalotuzumab 10 mg/kg 1 week + cetuximab + irinotecan versus |
Total enrolled 345 WT | 3.3 mos. | 10.8 mos. |
PFS: NR OS: NR | | dalotuzumab 7.5 mg/kg q 2 weeks versus | 5.4 mos. | 11.6 mos. | | placebo + cetuximab + irinotecan | 5.6 mos. | 14.0 mos. | |
|
|
WT: wild type, PFS: progression free survival, OS: overall survival, NR: not reported.
|